PDCD1 and cancer: Immune checkpoint therapy, represented by PD-1/PD-L1 inhibitors, is considered to have completely changed the cancer treatment landscape and has a good therapeutic effect on a variety of cancers, but not all patients respond, and with treatment progresses, drug resistance emerges (2, 3).